A Newly Synbiotic Combination Alleviates Obesity By Modulating The Gut Microbiota-Fat Axis

Objective:Obesity has been recognized as a worldwide public health crisis,and it is accompanied by dysregulation of the intestinal microbiota and upregulation of liver steatosis and adipose inflammation.As a novel alternative therapy for obesity,Synbiotic combination has recently gained much attention.Thus,we innovatively research the antiobesity properties of a Newly Synbiotic Combination composed of Lactobacillus acidophilus,Bifidobacterium infantis and konjac glucomannan oligosaccharides.Methods:In this study,C57BL/6J mice were performed divided randomly into three groups:normal chow diet(NCD)-group,high-fat diet(HFD)-group and HFD-fed Synbiotic treatment(HFD-Syn)-group.The HFD-induced obese mice were orally administered with a Newly Synbiotic Combination composed of Lactobacillus acidophilus,Bifidobacterium infants and konjac glucomannan oligosaccharides for 12 weeks.The intestinal permeability of mice in vivo was measured one week prior to euthanasia.Body weight,fat accumulation,inflammation,and energetic metabolism markers in multiple tissues were examined.Furthermore,we sequenced the 16 S rRNA of fecal samples derived from mice,and followed by performing bioinformatics analyses including gut microbiota composition analysis,Bug Base microbial phenotype prediction,and PICRUSt bacterial function prediction to investigate the biological effects of the Synbiotic in vivo.Results:Our study showed that Synbiotic treatment can reduce body weight,fat mass,blood sugar,liver steatosis and adipose inflammation in HFD-Syn-group than HFD-group.Meanwhile,Synbiotic treatment activated brown adipose tissue and improved energy,glucose and lipid metabolism.In addition,our data suggested that Synbiotic not solely enhanced the protection of the intestinal barrier,which reduced endotoxemia and then inhibited inflammation through the TLR4/NF-κB signaling pathway,but also ameliorated gut microbiota dysbiosis directly by enhancing beneficial microbes B.longum,B.pseudolongum,L.johnsonii,etc.and reducing potentially harmful bacteria such as Lachnospiraceae＿bacterium＿28-4 and Romboutsia＿ilealis,and Gram-negative bacteria levels.Furthermore,the results of microbiome phenotype prediction by Bug Base and bacterial functional potential prediction using PICRUSt showed that Synbiotic treatment can improve the gut microbiota functions involving inflammatory state,immune response,metabolism and pathopoiesia.What’s more,the Newly Synbiotic Combination achieved a16.86 percent weight loss effect in the HFD mice.Conclusion:Our Synbiotic Combination may be an effective candidate treatment strategy for the clinical prevention and treatment of obesity and other associated metabolic diseases such as hyperlipidemia and nonalcoholic fatty liver diseases by alleviating inflammatory response,regulating energy metabolism and maintaining the balance of intestinal microecology.